Margarida Maia, PhD, science writer —

Minimal residual disease or MRD — defined as a very small number of cancer cells that remain in the body during or after treatment —…

Adding elraglusib, a small molecule being developed by Actuate Therapeutics, to standard chemotherapy with gemcitabine and nab-paclitaxel (GnP) as a first-line treatment for metastatic…

Treatment with Zynlonta (loncastuximab tesirine) is helping to push high-risk follicular lymphoma and marginal zone lymphoma into complete remission for a majority of the…

Bizengri (zenocutuzumab-zbco) is now approved in the U.S. as the first treatment for advanced pancreatic cancer and non-small cell lung cancer (NSCLC) harboring an…

Treovir has launched a Phase 2 clinical trial to assess the safety and efficacy of G207, an experimental virus-based therapy, for pediatric recurrent high-grade…

Adding Keytruda (pembrolizumab) to chemotherapy, followed by maintenance treatment with Lynparza (olaparib), delayed cancer progression more effectively than chemotherapy alone in women with…

For about one-third of women with a neuroendocrine tumor — or an abnormal mass of tissue that forms from hormone-releasing cells, such as those in…

The U.S. Food and Drug Administration (FDA) will review GSK’s request to approve Blenrep (belantamab mafodotin) as part of a combination treatment for adults…

AbbVie’s Elahere (mirvetuximab soravtansine) has been approved in the European Union to treat adults with advanced ovarian, fallopian tube, or primary peritoneal cancer whose…

The subcutaneous (under-the-skin) formulation of Darzalex (daratumumab) has been approved in the European Union as part of a combination treatment for adults with newly…